Diagnosis of iddm with a panel of immunoreagents

Details Diagnosis of iddm with a panel of immunoreagents Diagnosis of iddm with a panel of immunoreagents

G - Physics

01

N

G01N 33/564 (2006.01) G01N 33/543 (2006.01) G01N 33/573 (2006.01) G01N 33/68 (2006.01) G01N 33/74 (2006.01)

Patent

CA 2095278

ABSTRACT OF THE DISCLOSURE Diagnosis of insulin-dependent (Type I) diabetes mellitus (IDDM) by contacting a blood sample from a patient with an immunoreagent comprising epitopes of two or more of glutamic acid decarboxylase (GAD) and the pancreatic islet cell antigens referred to as ICA512 and ICA12. Binding of antibodies present in the blood sample with one or more of such epitopes correlates with IDDM or a potential for developing IDDM. In clinical testing, about 80 percent of sera from newly diagnosed IDDM patients react positively with at least one epitope in a GAD/ICA512 panel. Reactivity with the GAD/ICA512/ICA12 panel is between about 80 and 90 percent. The method is useful in screening patients for pre-IDDM, for distinguishing IDDM from Type II diabetes, and for monitoring therapy. MS-9262

Affiliated with

Also associated with

Rating

Diagnosis of iddm with a panel of immunoreagents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diagnosis of iddm with a panel of immunoreagents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis of iddm with a panel of immunoreagents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1852882